Logo

American Heart Association

  30
  0


Final ID: Mo3071

Long-term Cardiovascular Outcomes and Predictors of Sodium Glucose Cotransporter 2 Inhibitor in Takotsubo Cardiomyopathy: A Propensity Matched National Analysis of The Trinetx Database

Abstract Body (Do not enter title and authors here): Background
Takotsubo cardiomyopathy (TTS) is a transient cardiac dysfunction often triggered by emotional or physical stress. While sodium-glucose cotransporter-2 (SGLT-2) inhibitors have shown cardioprotective effects in various cardiovascular conditions, their impact on TTS remains unclear. This study aimed to evaluate the long-term outcomes of TTS patients treated with SGLT-2 inhibitors compared to those who were not.

Methods
A retrospective cohort study was conducted using the United States TriNetX platform from 66 healthcare organizations. Patients diagnosed with TTS between 2012 and 2023 were identified and stratified into those initiated on SGLT-2 inhibitors within 14 days of diagnosis and those who were not. Propensity score matching (PSM) was performed on baseline characteristics to balance the cohorts (n=1,318 each). The primary outcomes included all-cause mortality. Secondary outcomes included left ventricular ejection fraction (LVEF) improvement and major adverse cardiovascular events (MACE). Predictors of mortality and LVEF improvement were also analyzed using the Cox proportional hazards model.

Results
After PSM, the TTS-SGLT2 cohort exhibited a significantly lower all-cause mortality rate compared to the TTS-NoSGLT2 cohort (HR=0.741, 95% CI 0.57 - 0.96, p 0.008). LVEF improvement was observed in TTS-SGLT patients (HR 1.55, 95% CI 1.09 - 2.203, p 0.04). Rates of heart failure hospitalizations, cardiogenic shock, and MACE were similar between the groups. Predictors of mortality included male sex, advanced age, diabetes mellitus, chronic kidney disease, hepatic fibrosis, convulsions, peripheral vascular disease, atrial fibrillation, and dementia, whereas predictors of LVEF improvement included younger age, and obesity.

Conclusion
The use of SGLT-2 inhibitors in patients with TTS was associated with a significant reduction in all-cause mortality and a positive impact on LVEF recovery. Further prospective studies are needed to validate these findings and explore the underlying mechanisms.
  • Sandhyavenu, Harigopal  ( UT Health San Antonio , San Antonio , Texas , United States )
  • Taha, Ahmed  ( Helwan University , Helwan , Egypt )
  • Younas, Hafiz Muhammad Umair  ( King Edward Medical University , Lahore , Pakistan )
  • Othman, Mohammed  ( Helwan University , Helwan , Egypt )
  • Lacoste, Jordan  ( WVU Medicine , Fairmont , West Virginia , United States )
  • Thyagaturu, Harshith  ( West Virginia University Heart and Vascular Institute , Morgantown , West Virginia , United States )
  • Balla, Sudarshan  ( West Virginia University Heart and Vascular Institute , Morgantown , West Virginia , United States )
  • Younas, Hafiz Muhammad Waqar  ( Weiss Memorial Hospital, Chicago , Chicago , Illinois , United States )
  • Taha, Amro  ( West Virginia University Heart and Vascular Institute , Morgantown , West Virginia , United States )
  • Atti, Lalitsiri  ( Michigan State University , Lansing , Michigan , United States )
  • Alruwaili, Waleed  ( West Virginia University , Morgantown , West Virginia , United States )
  • Al Hajji, Mohamed  ( West Virginia University Heart and Vascular Institute , Morgantown , West Virginia , United States )
  • Mubeen, Hafiz Khizer  ( King Edward Medical University , Lahore , Pakistan )
  • Safi, Layan  ( Chicago Medical School at Rosalind Franklin University of Medicine & Science , CHICAGO , Illinois , United States )
  • Al Hajji, Alaa  ( University of Sharjah , Sharjah , United Arab Emirates )
  • Author Disclosures:
    Harigopal Sandhyavenu: DO NOT have relevant financial relationships | Ahmed Taha: No Answer | Hafiz Muhammad Umair Younas: No Answer | Mohammed Othman: DO NOT have relevant financial relationships | Jordan Lacoste: DO NOT have relevant financial relationships | Harshith Thyagaturu: DO NOT have relevant financial relationships | sudarshan balla: DO NOT have relevant financial relationships | Hafiz Muhammad Waqar Younas: DO NOT have relevant financial relationships | Amro Taha: DO NOT have relevant financial relationships | Lalitsiri Atti: DO NOT have relevant financial relationships | Waleed Alruwaili: DO NOT have relevant financial relationships | Mohamed Al Hajji: DO NOT have relevant financial relationships | Hafiz Khizer Mubeen: No Answer | Layan Safi: DO NOT have relevant financial relationships | Alaa Al Hajji: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Real-World Use of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure

Monday, 11/10/2025 , 10:30AM - 11:30AM

Abstract Poster Board Session

More abstracts from these authors:
Comparative Outcomes of Bivalirudin Versus Heparin in Cardiogenic Shock Patients Supported with Impella Device: A Propensity-Matched Multicenters Analysis

Atti Lalitsiri, Kumar Rohan, Safi Layan, Al Hajji Alaa, Thyagaturu Harshith, Balla Sudarshan, Younas Hafiz Muhammad Waqar, Taha Amro, Taha Ahmed, Mubeen Hafiz Khizer, Othman Mohammed, Younas Hafiz Muhammad Umair, Alruwaili Waleed, Al Hajji Mohamed

Association of Angiotensin Receptor-Neprilysin Inhibitor Initiation With Mortality and Organ Failure Post Non-Acute Myocardial Infarction Cardiogenic Shock: A Multicenter Propensity Matched Retrospective Study

Taha Amro, Othman Mohammed, Al Hajji Mohamed, Lacoste Jordan, Thyagaturu Harshith, Bianco Christopher, Mondal Avilash, Atti Lalitsiri, Younas Hafiz Muhammad Waqar, Sandhyavenu Harigopal, Taha Ahmed, Mubeen Hafiz Khizer, Younas Hafiz Muhammad Umair, Safi Layan

You have to be authorized to contact abstract author. Please, Login
Not Available